BioNTech Results Presentation Deck

Global BNT162 clinical development program ongoing Phase 1/2 trials ongoing in Europe and US Testing of 4 vaccine candidates across different countries ● ● ● ● ● Designs Europe: dose escalation part up to 200 healthy subjects aged 18 to 55 US: seamless study design with several thousand subjects; Initial dose-finding part up to 360 healthy subjects aged 18-85 Dose range 1 µg to 100 µg Single-dose and 2-dose regimens to be tested in initial trial ● ● ● Evaluating safety, efficacy and optimal dose Evaluating effects of repeated immunization for 3 candidates using uRNA or modRNA and one prime-only using saRNA 6 Potentially accelerated approval pathways being discussed with global. regulators First cohorts dosed in each geography First clinical data expected June/July 2020 Prime / boost vaccine Boost Injektion-2 Strong Immunity Protecting Immunity No Immunity Strong Immunity Prime-only vaccine 1. Injektion Protecting Immunity Prime Injektion-1 No Immunity Weeks Weeks Months Months Immunity Immunity Years Years BIONTECH

View entire presentation